drugset
drugset / Trial / NCT05681390

Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

NCT05681390 ↗

Phase 2 Unknown 30 enrolled First Affiliated Hospital Xi'an Jiaotong University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, one-arm, phase II clinical study of Tislelizumab Combined With Anlotinib and Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic Cancer

Timeline

Start
2023-01-01
Primary completion
2024-12-31
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

pancreatic neoplasm